Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism
- PMID: 12484710
- DOI: 10.7326/0003-4819-137-12-200212170-00008
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism
Abstract
Background: The optimum duration of anticoagulant therapy after an episode of deep venous thrombosis (DVT) is controversial. Contributing to the controversy is uncertainty about whether residual venous thrombosis, as assessed by repeated ultrasonography over time, increases the risk for recurrent thromboembolism.
Objective: To determine the risk for recurrent thromboembolism in patients who have persistent residual thrombosis compared with patients who have early vein recanalization.
Design: Prospective cohort study.
Setting: A university hospital in Padua, Italy.
Patients: 313 consecutive symptomatic outpatients with proximal DVT who received conventional short-term anticoagulation.
Measurements: Ultrasonographic assessment of the common femoral and popliteal veins was performed 3 months after acute DVT in all patients and at 6, 12, 24, and 36 months in patients found to have residual venous thrombosis. Veins were considered recanalized if they were 2.0 mm or less in diameter on a single test or 3.0 mm or less in diameter on two consecutive tests. Recurrent thromboembolism was assessed during a 6-year period.
Results: The cumulative incidence of normal results on ultrasonography was 38.8% at 6 months, 58.1% at 12 months, 69.3% at 24 months, and 73.8% at 36 months. Of 58 recurrent episodes, 41 occurred while the patient had residual thrombosis. The hazard ratio for recurrent thromboembolism was 2.4 (95% CI, 1.3 to 4.4; P = 0.004) for patients with persistent residual thrombosis versus those with early vein recanalization.
Conclusions: Residual venous thrombosis is an important risk factor for recurrent thromboembolism. Ultrasonographic assessment of residual venous thrombosis may help clinicians modify the duration of anticoagulation in patients with DVT.
Comment in
-
Residual venous thrombosis and recurrent thromboembolism.Ann Intern Med. 2003 Aug 19;139(4):303; author reply 304. doi: 10.7326/0003-4819-139-4-200308190-00016. Ann Intern Med. 2003. PMID: 12965989 No abstract available.
-
Residual venous thrombosis and recurrent thromboembolism.Ann Intern Med. 2003 Aug 19;139(4):303-4; author reply 304. doi: 10.7326/0003-4819-139-4-200308190-00018. Ann Intern Med. 2003. PMID: 12965990 No abstract available.
-
Residual venous thrombosis and recurrent thromboembolism.Ann Intern Med. 2003 Aug 19;139(4):303; author reply 304. doi: 10.7326/0003-4819-139-4-200308190-00017. Ann Intern Med. 2003. PMID: 12965991 No abstract available.
Summary for patients in
-
Summaries for patients. Risks for persistent clots in leg veins despite treatment.Ann Intern Med. 2002 Dec 17;137(12):I32. doi: 10.7326/0003-4819-137-12-200212170-00003. Ann Intern Med. 2002. PMID: 12484741 No abstract available.
Similar articles
-
Risk factors of recurrent venous thromboembolism: the role of residual vein thrombosis.Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):351-3. doi: 10.1159/000083827. Pathophysiol Haemost Thromb. 2003. PMID: 15692242 Review.
-
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.Ann Intern Med. 2009 May 5;150(9):577-85. doi: 10.7326/0003-4819-150-9-200905050-00003. Ann Intern Med. 2009. PMID: 19414836 Clinical Trial.
-
The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis.Thromb Haemost. 2002 Sep;88(3):402-6. Thromb Haemost. 2002. PMID: 12353067
-
Summaries for patients. Risks for persistent clots in leg veins despite treatment.Ann Intern Med. 2002 Dec 17;137(12):I32. doi: 10.7326/0003-4819-137-12-200212170-00003. Ann Intern Med. 2002. PMID: 12484741 No abstract available.
-
Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis.JAMA. 2010 Feb 3;303(5):438-45. doi: 10.1001/jama.2010.43. JAMA. 2010. PMID: 20124539 Review.
Cited by
-
Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review.Rev Cardiovasc Med. 2023 Oct 19;24(10):295. doi: 10.31083/j.rcm2410295. eCollection 2023 Oct. Rev Cardiovasc Med. 2023. PMID: 39077577 Free PMC article. Review.
-
Which one is the best in treating deep venous thrombosis -- percutaneous mechanical thrombectomy, catheter-directed thrombolysis or combination of them?J Cardiothorac Surg. 2024 Jul 5;19(1):423. doi: 10.1186/s13019-024-02908-3. J Cardiothorac Surg. 2024. PMID: 38970107 Free PMC article.
-
To Compare the Effectiveness of Low-Molecular-Weight Heparin and Unfractionated Heparin in Reducing Lower Limb Girth in Deep Vein Thrombosis.Cureus. 2024 May 1;16(5):e59449. doi: 10.7759/cureus.59449. eCollection 2024 May. Cureus. 2024. PMID: 38827007 Free PMC article.
-
The Below-the-Knee Approach to Percutaneous Mechanical Thrombectomy for Lower Extremity Deep Venous Thrombosis: A Retrospective Single-Centre, Single-Arm Study.Ann Thorac Cardiovasc Surg. 2024;30(1):24-00015. doi: 10.5761/atcs.oa.24-00015. Ann Thorac Cardiovasc Surg. 2024. PMID: 38538311 Free PMC article.
-
Venous thromboembolism: diagnostic advances and unaddressed challenges in management.Curr Opin Hematol. 2024 May 1;31(3):122-129. doi: 10.1097/MOH.0000000000000809. Epub 2024 Feb 12. Curr Opin Hematol. 2024. PMID: 38359323 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical